# A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients

Study · id `cardio:ct-nct02996721` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02996721](<https://clinicaltrials.gov/study/NCT02996721>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02996721

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 634 participants.

## Technical summary

Registry record NCT02996721. Randomized; no masking; primary purpose treatment. Start 2017-04-03 (actual); primary completion 2025-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 634 participants (enrolled count; ClinicalTrials.gov record NCT02996721, source copy `cardio:ctgov-nct02996721-2026-11-05`, retrieved 2026-11-18)
- Started: 2017-04-03 (actual) (ClinicalTrials.gov record NCT02996721, source copy `cardio:ctgov-nct02996721-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2025-03-30 (actual) (ClinicalTrials.gov record NCT02996721, source copy `cardio:ctgov-nct02996721-2026-11-05`, retrieved 2026-11-18)
- Completion: 2025-09-04 (actual) (ClinicalTrials.gov record NCT02996721, source copy `cardio:ctgov-nct02996721-2026-11-05`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT02996721, source copy `cardio:ctgov-nct02996721-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02996721-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
- Acronym: TARGET-D
- Condition: Death
- Condition: Myocardial Infarction
- Condition: Cerebral Vascular Accident
- Condition: Heart Failure Hospitalization
- Intervention (Biological): Vitamin D3
- Lead sponsor: Intermountain Health Care, Inc.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Intermountain Health Care, Inc. (`cardio:org-intermountain-health-care-inc`)

## Provenance

Content hash: 1cdfbd50ffc1bb0b752ac94290693e079e59c6188af012e891d8010bd8e214cf
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
